Bioxytran, Inc. (BIXT)
| Market Cap | 3.85M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -2.12M |
| Shares Out | 113.36M |
| EPS (ttm) | -0.02 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 230,000 |
| Average Volume | 198,787 |
| Open | 0.0350 |
| Previous Close | 0.0332 |
| Day's Range | 0.0325 - 0.0350 |
| 52-Week Range | 0.0262 - 0.1743 |
| Beta | 2.52 |
| RSI | 39.91 |
| Earnings Date | May 14, 2026 |
About Bioxytran
Bioxytran, Inc., a clinical stage pharmaceutical company, focuses on the development, manufacture, and commercialization of therapeutic drugs to address hypoxia in humans. The company’s lead drug candidate is BXT-25, an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer for use in the treatment of hypoxic conditions in the brain resulting from stroke, and hypoxic conditions in wounds to prevent necrosis and to promote healing. It is also developing ProLectin-Rx, a polysaccharide derived from pectin that ... [Read more]
Financial Performance
Financial StatementsNews
BIOXYTRAN, INC. COMPLETES $1.2 MILLION PRIVATE PLACEMENT
Financing strengthens balance sheet and supports advancement of key development initiatives NEWTON, MA, March 20, 2026 (GLOBE NEWSWIRE) -- Bioxytran, Inc. (OTC: BIXT), a clinical-stage biotechnology c...
Bioxytran Announces Positive Dose Optimization Results and Advances Toward Phase 3 Registrational Trial for ProLectin-M
Company Initiates Regulatory Discussions with CDSCO; Plans 408-Patient Pivotal Study Targeting Standard-Risk Several Viral Infected Outpatients BOSTON, March 04, 2026 (GLOBE NEWSWIRE) -- Bioxytran, In...
Bioxytran, Inc. Reports Positive Phase 1b/2a Clinical Study Results for ProLectin-M, a Broad-Range Antiviral Drug in Mild to Moderate COVID-19
BOSTON, MA / ACCESS Newswire / March 2, 2026 / Bioxytran, Inc. (OTCQB:BIXT), a clinical-stage biotechnology company developing carbohydrate-based therapeutics, today announced results from a randomize...
Bioxytran Reports Positive Phase 2 Results Demonstrating Rapid Viral Clearance with ProLectin-MBioxytran
BOSTON, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Bioxytran, Inc. ( OTCQB: BIXT) today announced positive clinical results from its recently completed Phase 2 randomized, double-blind, placebo-controlled, do...
Bioxytran Transcript: Noble Capital Markets’ Emerging Growth Virtual Equity Conference
A novel antiviral based on polysaccharide galectin antagonists showed rapid viral clearance in phase II trials, with no adverse effects and broad-spectrum potential. The company is pursuing both nutraceutical commercialization and drug approval, with additional pipeline assets in oxygen delivery for stroke.
Bioxytran and University of Minnesota Launch Sponsored Research Collaboration to Advance Novel Carbohydrate-Based Therapeutics
NEEDHAM, Mass., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Bioxytran, Inc. (OTCQB: BIXT) (“Bioxytran” or the “Company”), a clinical-stage biotechnology company developing platform technologies spanning glycovi...
Bioxytran Transcript: Emerging Growth Conference 88
A clinical stage biotech is advancing three carbohydrate-based platforms targeting antivirals, stroke, and cancer metastasis, with a lead drug showing 100% viral reduction in trials. Top-line data is expected soon, and new partnerships are being pursued, including for immunotherapy and bird flu research.
Bioxytran Announces Initiation of Coverage of its Stock by Independent Research
BOSTON, MASSACHUSETTS, Nov. 13, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical-stage biotech company focused on innovative treatments for stroke, Alzheimer's, and v...
Bioxytran Completes Randomized Clinical Trial For its Broad-Spectrum Antiviral Drug
BOSTON, MASSACHUSETTS, Oct. 29, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company pioneering innovative therapies for viral diseases, is pl...
Bioxytran Unveils Revolutionary Precision Diagnostics on Tissue Oxygenation
BOSTON, MASSACHUSETTS, Aug. 15, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a pioneering clinical stage biotechnology company at the forefront of oxygen therapeutics, is pr...
Bioxytran's Breakthrough Broad-Spectrum Antiviral Technology Poised to Revolutionize Respiratory Infection Treatment
- ProLectin-M is currently being developed under an active Investigational New Drug (IND) application with the FDA BOSTON, MASSACHUSETTS, Aug. 07, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT...
Bioxytran Transcript: Emerging Growth Conference 83
Three AI-driven platform technologies were showcased, including a broad-spectrum antiviral with strong clinical results, an oxygenation molecule leveraging camel hemoglobin, and a cancer metastasis treatment. The company highlighted undervaluation, ongoing licensing, and upcoming clinical and funding milestones.
Bioxytran Secures a Source of GMP Quality Camel Hemoglobin
- First use of camel hemoglobin as a universal oxygen carrier - Unique properties make it an ideal ingredient for oxygen transport BOSTON, MASSACHUSETTS, June 18, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN, I...
Bioxytran's Groundbreaking Stroke & Alzheimer's Tech Gains Validation That Measures Oxygenation Uptake During Strokes
Mongolian Gerbil Research Unlocks Critical Insights for Ischemic Stroke and Neurodegenerative Disease Treatments
Bioxytran's Antiviral Breakthrough Featured in University of Georgia's $100M HPAI Poultry Innovation Grand Challenge Submission
PHM23 was one of a handful of molecules chosen by the university Bird Flu helping PHM23 gain awareness of broad-spectrum activity at a university level BOSTON, MASSACHUSETTS, May 21, 2025 (GLOBE NEWSW...
Bioxytran Completes Dose Optimization of Antiviral, ProLectin-M
BOSTON, MASSACHUSETTS, May 12, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing novel antiviral therapies, today announced the ...
Bioxytran Marks 50 years of Mitochondrial Research with BXT-25 Advancements
- The universal oxygen carrier delivery capabilities of BXT-25 can be monitored, broadening its applications to treat hypoxic diseases
Bioxytran Transcript: Emerging Growth Virtual Conference
Three AI-driven platform technologies are advancing, including a broad-spectrum antiviral with strong clinical results and a scalable bird flu solution. Licensing and academic partnerships are central to growth, while recent financial restructuring has positioned the company for new funding and collaborations.
Bioxytran Signs NDA with the University of Georgia to Evaluate Galectin Antagonists for Bird Flu Treatment in Chickens
In Vitro studies have shown promise against viruses similar to the bird flu virus BOSTON, MASSACHUSETTS, March 19, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical st...
Bioxytran Develops a Groundbreaking Treatment to Combat Bird Flu in Egg Laying Chickens Potentially Saving Billions
New water-soluble galectin antagonist being considered in preclinical trials offering hope for rapid containment to H5N1 outbreaks
Bioxytran Transcript: Emerging Growth Conference 79
Three AI-driven platform technologies target viral infections, cancer, and oxygenation, with clinical data showing rapid viral clearance and promising cancer combination therapy results. The company is pursuing licensing, government partnerships, and rebranding as an inflammation-focused innovator.
Bioxytran Transcript: Emerging Growth Virtual Conference 78
Three AI-driven platform technologies target viral, oxygenation, and cancer indications, with clinical data showing 100% viral reduction and strong safety. Recent BARDA engagement highlighted funding opportunities and government interest, especially in broad-spectrum antivirals and oxygen carriers.
Bioxytran's Cancer Preprint Reveals Potential to Enhance Most Immunotherapy Drugs
BOSTON, MASSACHUSETTS, Jan. 10, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing oral and intravenous drugs to treat viral dise...
Bioxytran's Medical Breakthrough in Fighting All Viruses
Breakthrough was validated in the latest journal article Galectins are essential for viral entry and a new target for drug development Carbohydrates were shown to neutralize viruses Blocking galectins...
Presenting on the Emerging Growth Conference 74 Day 1 on August 21 Register Now
MIAMI, Aug. 20, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 74th Emerging Growth Conference on August 21 – 22, 2024.